J.P. Morgan Securities LLC Xeris Pharmaceuticals, Inc 8.3 amend (0093C)
15 Junho 2021 - 1:55PM
UK Regulatory
TIDM0A8E
RNS Number : 0093C
J.P. Morgan Securities LLC
15 June 2021
Ap19
AMENDMENT
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing J.P. Morgan Securities
(Note 1) LLC
Company dealt in Xeris Pharmaceuticals,
Inc.
======================
Class of relevant security $0.001 common stock
to which the dealings
being disclosed relate
(Note 2)
======================
Date of dealing 09 June 2021
======================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant
security dealt in (Note 3)
Long Short
Number (%) Number (%)
========= ====== =========== ======
(1) Relevant securities 4,250,867 6.40 764,425 1.15
----------------- -------------------
(2) Derivatives (other
than options) 590,251 0.89
----------------- -------------------
(3) Options and agreements
to purchase/sell
----------------- -------------------
Total 4,841,118 7.29 764,425 1.15
----------------- -------------------
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit
(USD)
(Note 5)
Purchase (New 165,300 N/A
Borrow)
52,400 N/A
Purchase (Loan
Return) 2 4.1000 USD
1 4.0900 USD
Purchases 3 4.0733 USD
Purchases 8 4.0675 USD
Purchases 3 4.0633 USD
Purchases 1 4.0600 USD
Purchases 51 4.0598 USD
Purchases 23 4.0583 USD
Purchases 1 4.0500 USD
Purchases 4 4.0275 USD
Purchases 5 4.0240 USD
Purchases
Purchases 51 4.0598 USD
1,320 4.0100 USD
Sales 100 4.0025 USD
Sales 32 4.0000 USD
Sales
Sales
====================================== ====================
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant Price per
e.g. CFD (Note 6) securities unit
(Note 7) (USD) (Note
5)
Equity Swap Decrease Long 51 4.0598 USD
===================== ================== =============
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry Option
name, selling, securities price e.g. American, date money paid/received
e.g. call purchasing, to which European per unit
option varying the option etc. (Note 5)
etc. relates (Note
7)
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call option per unit (Note
5)
(d) Other dealings (including transactions in respect of new
securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable)
(Note 5)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred
to on this form or relating to the voting rights or future
acquisition or disposal of any relevant securities to which any
derivative
referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 15 June 2021
Contact name Alwyn Basch
=============
Telephone number 0207 742 7407
=============
If a connected EFM, name N/A
of offeree/offeror with
which connected
=============
If a connected EFM, state N/A
nature of connection (Note
10)
=============
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ISESFDFMIEFSEIM
(END) Dow Jones Newswires
June 15, 2021 12:55 ET (16:55 GMT)
Xeris Biopharma (LSE:0A8E)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Xeris Biopharma (LSE:0A8E)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
